Crescita Therapeutics Inc.

CTX

CA2258471028

Pharmaceuticals

Market Closed - Toronto S.E. Other stock markets 03:59:47 2024-04-26 pm EDT			5-day change	1st Jan Change
0.43 ^CAD	0.00%		-1.15%	-12.24%

Mar. 13	Crescita Therapeutics Reports Q4 Net Loss of $0.01 Per Share	MT
Mar. 13	Tranche Update on Crescita Therapeutics Inc.'s Equity Buyback Plan announced on August 29, 2023.	CI

Tranche Update on Crescita Therapeutics Inc.'s Equity Buyback Plan announced on August 29, 2023.

November 08, 2023 at 08:07 am EST

From August 29, 2023 to September 30, 2023, the company has repurchased 355,110 shares, representing 1.74% for CAD 0.24 million. With this, the company has completed the repurchase of 355,110 shares, representing 1.74% for CAD 0.24 million under the buyback announced on August 29, 2023.

Latest news about Crescita Therapeutics Inc.

Crescita Therapeutics Reports Q4 Net Loss of $0.01 Per Share	Mar. 13	MT
Tranche Update on Crescita Therapeutics Inc.'s Equity Buyback Plan announced on August 29, 2023.	Mar. 13	CI
Crescita Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 13	CI
Crescita Therapeutics Brief: Q4 EPS Basic and Diluted Loss $0.01	Mar. 13	MT
Crescita Therapeutics Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 13	CI
North American Morning Briefing : Stock Futures -2-	Mar. 13	DJ
Tranche Update on Crescita Therapeutics Inc.'s Equity Buyback Plan announced on August 29, 2023.	Nov. 08	CI
Crescita Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 08	CI
Crescita Therapeutics Obtains TSX Approval for Normal Course Issuer Bid	23-08-29	MT
Crescita Therapeutics Brief: Announced Approval of Normal Course Issuer Bid	23-08-29	MT
Crescita Therapeutics Inc. announces an Equity Buyback for 1,821,616 shares, representing 8.94% of its issued share capital.	23-08-29	CI
Crescita Therapeutics Inc. authorizes a Buyback Plan.	23-08-28	CI
- Crescita Therapeutics Brief: Q2 Revenue $5.162 Million; Ending cash was $10,226, down $49 for the quarter	23-08-09	MT
Crescita Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-09	CI
Crescita Therapeutics Inc. Announces Launch of Topical Anaesthetic Pliaglis(R) in Europe in Its European Core Markets Including Germany, the United Kingdom and Ireland	23-06-01	CI
Crescita Therapeutics Q1 Revenue was $4.6 Million; Cites Cash Balance of $10.3M	23-05-11	MT
Crescita Therapeutics Brief: Q1 Revenue was $4.602 Million; Cites Cash Balance of $10.3M	23-05-11	MT
Crescita Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11	CI
Crescita Therapeutics Reports Q4 Revenue of $6.03 Million, EPS of $0.06	23-03-15	MT
Crescita Therapeutics Brief: Q4 Revenue was $6,030,000 compared to $7,562,000; Adjusted EBITDA was $997,000	23-03-15	MT
Crescita Therapeutics Inc. acquired unknown minority stake in Akyucorp Ltd. for CAD 0.06 million.	23-03-14	CI
Tranche Update on Crescita Therapeutics Inc.'s Equity Buyback Plan announced on December 15, 2021.	23-03-14	CI
Crescita Therapeutics Inc.'s Equity Buyback announced on December 15, 2021, has expired with 663,600 shares, representing 3.19% for CAD 1.06 million.	22-12-15	CI
Crescita Therapeutics Reports Q3 Revenue of $6 Million; EPS C$0.01; Cash Balance of $10.7 Million	22-11-09	MT
Tranche Update on Crescita Therapeutics Inc.'s Equity Buyback Plan announced on December 15, 2021.	22-11-09	CI

Chart Crescita Therapeutics Inc.

Duration

Period

More charts

Company Profile

Crescita Therapeutics Inc. is a commercial dermatology company with in-house research and development (R&D) and manufacturing capabilities. It offers a portfolio of science-based non-prescription skincare products and early to commercial stage prescription products. It operates in three segments: Commercial Skincare, Licensing and Royalties and Manufacturing and Services. The Commercial Skincare segment manufactures and sells branded non-prescription skincare products for the Canadian and international markets. It also commercializes Pliaglis, NCTF Boost 135 HA, ART FILLER and Obagi Medical in Canada. The Licensing and Royalties segment engaged in licensing the intellectual property related to Pliaglis or its transdermal delivery technologies. Manufacturing and Services segment engaged in the sale of topical products manufactured to client specifications under the Companyâs contract development and manufacturing organization infrastructure, and sales of product development services.

Sector

Pharmaceuticals

Calendar

2024-05-07 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
CRESCITA THERAPEUTICS INC.	-12.24%	6.12M
ELI LILLY AND COMPANY	+25.83%	661B
NOVO NORDISK A/S	+27.00%	566B
JOHNSON & JOHNSON	-6.76%	352B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+3.00%	283B
ASTRAZENECA PLC	+13.09%	231B
NOVARTIS AG	+5.46%	200B
ROCHE HOLDING AG	-9.61%	195B
AMGEN INC.	-6.26%	145B

Other Pharmaceuticals

Crescita Therapeutics Inc.

Equities

CTX

CA2258471028

Pharmaceuticals

Tranche Update on Crescita Therapeutics Inc.'s Equity Buyback Plan announced on August 29, 2023.

Latest news about Crescita Therapeutics Inc.

Chart Crescita Therapeutics Inc.

Company Profile

Income Statement Evolution

Sector Other Pharmaceuticals